Low-dose cinacalcet reduces serum calcium in patients with primary hyperparathyroidism not eligible for surgery;Dosis bajas de cinacalcet reducen el calcio sérico en pacientes con hiperparatiroidismo primario no subsidiario de tratamiento quirúrgico

Endocrinologia y Nutricion

Volumn 58, Issue 1, 2011, Pages 24-31

  Arranz Martín, Alfonso ^a   Villalón, Andrea Azcárate ^a   Ramírez, Manuel Luque ^a   Durán, Blanca Santana ^a   Azpíroz, Mónica Marazuela ^a   Ruiz, Amalia Paniagua ^a   Carraro, Raffaele ^a   Pan, Antonio Gómez ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Calcium mimetics; Cinacalcet; Primary hyperparathyroidism

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; CINACALCET; PARATHYROID HORMONE; PHOSPHATE;

ADULT; AGED; ARTICLE; ASTHENIA; CALCIUM BLOOD LEVEL; CALCIUM METABOLISM; CALCIUM URINE LEVEL; CLINICAL ARTICLE; DIZZINESS; DRUG TOLERANCE; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; MALE; PARATHYROIDECTOMY; PHOSPHATE BLOOD LEVEL; PRIMARY HYPERPARATHYROIDISM; WEAKNESS;

ADULT; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; ASTHENIA; CALCIUM; DOSE-RESPONSE RELATIONSHIP, DRUG; FATIGUE; FEMALE; HUMANS; HYPERCALCEMIA; HYPERPARATHYROIDISM, PRIMARY; MALE; MIDDLE AGED; NAPHTHALENES; NAUSEA; PARATHYROID HORMONE; PARATHYROIDECTOMY; PHOSPHORUS; PROSPECTIVE STUDIES; VITAMIN D;

EID: 79251615292     PISSN: 15750922     EISSN: 15792021     Source Type: Journal    
DOI: 10.1016/j.endonu.2010.09.009     Document Type: Article

References (20)

1. Silverberg S.J., Lewiecki E.M., Mosekilde L., Peacock M., Rubin M.R. Presentation of asymptomatic primary hyperparathyroidism: Proccedings of the Third International Workshop. J Clin Endocrinol Metab. 2009, 9:351-355.
2. Bilezikian J.P., Khan A.A., Potts J.T. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Third International Workshop. J Clin Endocrinol Metab. 2009, 94:335-339.
3. Barman Balfour J.A., Scott L.J. Cinacalcet hydrochloride. Drugs. 2005, 65:271-281.
4. Padhi D., Harris R. Clinical pharmacokinetic and pharamcodynamic profile of cinacalcet hydrochloride. Clin Pharmacokinet. 2009, 48:303-311.
5. EMEA. Mimpara (cinacalcet hydrocholidre). Summary of product characteristics, 2009.
6. Iglesias P., Ais G., González A., Tajada P., Arévalo C., García C., et al. Acute and One-Year Effects of Cinacalcet in Patients With Persistent Primary Hyperparathyroidism After Unsuccessful Parathyroidectomy. Am J Med Sci. 2008, 335:111-114.
7. Díaz Guardiola P., Vega Piñero B., Alameda Hernando C., Pavón de Paz I., Iglesias Bolaños P., Guijarro de Armas G. Primary hyperparathyroidism. An alternative to the surgery. Endocrinol Nutr. 2009, 56:132-135.
8. 2+-sensing receptor from bovine parathyroid. Nature. 1993, 366:575-580.
9. Goodman W.G., Turner S.A. Future role of calcimimetics in end-stage renal disease. Adv Ren Replace Ther. 2002, 9:200-208.
10. Moosgaard B., Vestergaard P., Heickendorff L., Melsen F., Christiansen P., Mosekilde L. Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism. Clin Endocrinol. 2008, 63:506-513.
11. Peacock M., Bolognese M.A., Borofsky M., Scumpia S., Sterling L.R., Cheng S., et al. Cinacalcet treatment of primary hyperparathyroidism: Biochemical and bone densitometric outcomes in a five-years study. J Clin Endocrinol Metab. 2009, 94:4860-4867.
12. Dong B.J. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism. Clin Ther. 2005, 27:1725-1751.
13. Hirai T., Nakashima A., Takasugi N., Yorioka N. Response of secondary hyperparathyroidism to cinacalcet depends on parathyroid size. Nephron Clin Pract. 2010, 114:187-193.
14. Silverberg S.J., Rubin M.R., Faiman C., Peacock M., Shoback D.M., Smallridge R.C., et al. Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J Clin Endocrinol Metab. 2007, 92:3803-3808.
15. Peacock M., Bilezikian J.P., Klassen P.S., Guo M.D., Turner S.A., Shoback D. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab. 2005, 90:135-141.
16. Shoback D.M., Bilezikian J.P., Turner S.A., McCary L.C., Guo M.D., Peacock M. The Calcimimetic Cinacalcet Normalizes Serum Calcium in Subjects with Primary Hyperparathyroidism. J. Clin Endocrinol Metab. 2003, 88:5644-5649.
17. 2+-sensig receptor promotes loss of cancellous bone. Endocrinology. 2007, 148:3156-3163.
18. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Eng J Med. 2001, 144:1434-1441.
19. Nakaoka D., Sugimoto T., Kobayashi T., Yamaguchi T., Kobayashi A., Chihara K. Prediction of bone mass change after parathyroidectomy in patients with primary hyperparathyroidism. J Clin Endocrinol Metab. 2000, 85:1901-1907.
20. Marocci C., Chanson P., Shoback D., Bilezikian J., Fernández-Cruz L., Orgiazzi J., et al. Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. J Cin Endocrinol Metab. 2009, 94:2766-2772.